ES2234933T3 - Utilizacion de opiaceos debiles y mixtos agonistas/antagonistas para el tratamiento de la incontinencia urinaria. - Google Patents

Utilizacion de opiaceos debiles y mixtos agonistas/antagonistas para el tratamiento de la incontinencia urinaria.

Info

Publication number
ES2234933T3
ES2234933T3 ES01998335T ES01998335T ES2234933T3 ES 2234933 T3 ES2234933 T3 ES 2234933T3 ES 01998335 T ES01998335 T ES 01998335T ES 01998335 T ES01998335 T ES 01998335T ES 2234933 T3 ES2234933 T3 ES 2234933T3
Authority
ES
Spain
Prior art keywords
urinary incontinence
treatment
bladder
antagonists
codeine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES01998335T
Other languages
English (en)
Spanish (es)
Inventor
Thomas Christoph
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gruenenthal GmbH
Original Assignee
Gruenenthal GmbH
Chemie Gruenenthal GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal GmbH, Chemie Gruenenthal GmbH filed Critical Gruenenthal GmbH
Application granted granted Critical
Publication of ES2234933T3 publication Critical patent/ES2234933T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ES01998335T 2000-11-30 2001-11-28 Utilizacion de opiaceos debiles y mixtos agonistas/antagonistas para el tratamiento de la incontinencia urinaria. Expired - Lifetime ES2234933T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10059415 2000-11-30
DE10059415A DE10059415A1 (de) 2000-11-30 2000-11-30 Verwendung von schwachen Opioiden und gemischten Opioidagonisten/-antagonisten zur Therapie der Harninkontinenz

Publications (1)

Publication Number Publication Date
ES2234933T3 true ES2234933T3 (es) 2005-07-01

Family

ID=7665212

Family Applications (1)

Application Number Title Priority Date Filing Date
ES01998335T Expired - Lifetime ES2234933T3 (es) 2000-11-30 2001-11-28 Utilizacion de opiaceos debiles y mixtos agonistas/antagonistas para el tratamiento de la incontinencia urinaria.

Country Status (14)

Country Link
US (1) US7008939B2 (https=)
EP (1) EP1337254B1 (https=)
JP (1) JP2004527465A (https=)
AT (1) ATE287265T1 (https=)
AU (2) AU2002220736B2 (https=)
CA (1) CA2430281C (https=)
DE (2) DE10059415A1 (https=)
ES (1) ES2234933T3 (https=)
HU (1) HUP0303285A3 (https=)
MX (1) MXPA03004713A (https=)
NZ (1) NZ526604A (https=)
PL (1) PL204246B1 (https=)
PT (1) PT1337254E (https=)
WO (1) WO2002043713A2 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8476280B2 (en) 2002-05-09 2013-07-02 Versi Group, Llc Compositions and methods for combating lower urinary tract dysfunctions with delta opioid receptor agonists
US7964315B2 (en) * 2003-09-12 2011-06-21 Bdf Ip Holdings Ltd. Shutdown methods and designs for fuel cell stacks
JP4902883B2 (ja) * 2005-03-11 2012-03-21 ビーディーエフ アイピー ホールディングス リミテッド 燃料電池スタックのシャットダウン方法および設計
TW200800223A (en) * 2005-12-21 2008-01-01 Shire Pharmaceuticals Inc Transdermal delivery of meptazinol
US8748448B2 (en) 2007-10-18 2014-06-10 Aiko Biotechnology Combination analgesic employing opioid agonist and neutral antagonist
EP2214672B1 (en) * 2007-10-18 2012-10-17 Aiko Biotechnology Combination analgesic employing opioid and neutral antagonist
CN102836122A (zh) * 2011-06-24 2012-12-26 扬子江药业集团四川海蓉药业有限公司 含有盐酸美普他酚的组合物注射液及其制备方法
CN109646397A (zh) * 2015-02-13 2019-04-19 成都苑东生物制药股份有限公司 一种盐酸美普他酚注射液药物组合物及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5354863A (en) * 1992-01-21 1994-10-11 G. D. Searle & Co. Opioid agonist compounds
GB9202238D0 (en) * 1992-02-03 1992-03-18 Wellcome Found Compounds
USRE36547E (en) * 1992-09-21 2000-02-01 Albert Einstein College Of Medicine Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opioid agonists
US6159501A (en) * 1996-03-08 2000-12-12 Nycomed Danmark A/S Modified release multiple-units dosage composition for release of opioid compounds
US5859043A (en) * 1996-06-11 1999-01-12 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Method for maintaining kidney function during surgery or severe trauma under general anesthesia
EP1005861B1 (en) * 1997-04-11 2005-06-29 Nippon Shinyaku Co., Ltd. Remedies for frequent urination and urinary incontinence
US5840696A (en) * 1997-09-11 1998-11-24 Lippton; Howard Diuretic and antinatriuretic responses produced by the endogenous opioid-like peptide, nociceptin (orphanin FQ)
US6274591B1 (en) * 1997-11-03 2001-08-14 Joseph F. Foss Use of methylnaltrexone and related compounds
ATE210983T1 (de) * 1997-11-03 2002-01-15 Stada Arzneimittel Ag Stabilisiertes kombinationsarzneimittel enthaltend naloxone und ein opiatanalgetikum
DE19947747A1 (de) * 1999-10-05 2001-04-12 Gruenenthal Gmbh Verwendung von (+)-Tramadol, O-Demethyltramadol bzw. (+)-O-Demethyltramadol zur Therapie der Harninkontinenz
US8410129B2 (en) * 2002-02-15 2013-04-02 Howard Brooks-Korn Treatment for paresis/paralysis

Also Published As

Publication number Publication date
CA2430281C (en) 2009-08-25
HUP0303285A3 (en) 2005-05-30
PL204246B1 (pl) 2009-12-31
DE50105150D1 (de) 2005-02-24
AU2002220736B2 (en) 2006-04-06
JP2004527465A (ja) 2004-09-09
AU2073602A (en) 2002-06-11
WO2002043713A2 (de) 2002-06-06
US7008939B2 (en) 2006-03-07
WO2002043713A3 (de) 2002-10-31
ATE287265T1 (de) 2005-02-15
HUP0303285A2 (hu) 2004-01-28
CA2430281A1 (en) 2002-06-06
EP1337254A2 (de) 2003-08-27
PT1337254E (pt) 2005-05-31
NZ526604A (en) 2005-04-29
EP1337254B1 (de) 2005-01-19
DE10059415A1 (de) 2002-06-06
PL363677A1 (en) 2004-11-29
MXPA03004713A (es) 2003-08-19
US20040029905A1 (en) 2004-02-12

Similar Documents

Publication Publication Date Title
ES2291223T3 (es) Utilizacion de (+)-tramadol, o-demetiltramadol, o-desmetil-n-mono-desmetiltramadol para el tratamiento de la incontinencia urinaria.
CZ20012982A3 (cs) Derivát gabapentinu pro prevenci a léčbu viscerální bolesti
ES2263792T3 (es) Derivados de aril(o heteroaril) azolilcarbinoles para el tratamiento de la incontinencia urinaria.
WO2000025821A1 (en) Method of treating and diagnosing restless legs syndrome and corresponding means
ES2234933T3 (es) Utilizacion de opiaceos debiles y mixtos agonistas/antagonistas para el tratamiento de la incontinencia urinaria.
SK284937B6 (sk) Použitie prokineticky účinného antiemetika a tramadolu na výrobu liečiva na liečenie migrény
ES2311030T3 (es) Utilizacion de compuestos de 1-fenil-3-dimetilaminopropano para el tratamiento de la incontinencia urinaria.
ES2255607T3 (es) Utilizacion de buprenorfina para el tratamiento de la incontinencia urinaria.
ES2260306T3 (es) Utilizacion de compuestos 6-dimetilaminometil-1-fenilciclohexano para el tratamiento de incontinencia urinaria.
ES2256338T3 (es) Utilizacion de compuestos 6-dimetilaminometil-1-fenilciclohexano sustituidos para el tratamiento de la incontinencia urinaria.
EP2849747B1 (en) Pharmaceutical composition comprising (1r,4r)-6'-fluoro-n,n-dimethyl-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano [3,4,b]indol]-4-amine and a nsar
US20190350884A1 (en) Pharmaceutical composition comprising (1r,4r)-6'-fluoro-n,n-dimethyl-4-phenyl-4',9'-dihydro-3'h-spiro [cyclohexane-1,1'-pyrano-[3,4,b]indol]-4-amine and paracetamol or propacetamol
HK1204938B (en) Pharmaceutical composition comprising (1r,4r)-6'-fluoro-n,n-dimethyl-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano [3,4,b]indol]-4-amine and a nsar
HK1204940B (en) Pharmaceutical composition comprising (1r,4r)-6'-fluoro-n,n-dimethyl-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano'[3,4,b]indol]-4-amine and paracetamol or propacetamol